Company Financials

Mineralys Therapeutics, Inc. Financials

United States dollar

business Mineralys Therapeutics, Inc. Company Profile

Main Stock Listing

NASDAQ: MLYS

Market Capitalization None as of None

Market Cap History

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE -4.50
Price to Sales TTM $
Price to Book MRQ $2.21
Enterprise to Revenue
Enterprise to EBITDA -4.80

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends 2023-12-31
Most Recent Quarter 2023-12-31
Profit Margin 0.00%
Operating Margin 0.00%
Return on Assets TTM -28.91%
Return on Equity TTM -41.38%

Income Statement

Revenue TTM $0
Revenue per Share TTM $
Quarterly Revenue Growth %
Gross Profit TTM $0
EBITDA $0
Net Income to Common TTM $-71,898,000
Diluted EPS TTM $-1.99
Quarterly Earnings Growth YoY %

Balance Sheet

Total Cash MRQ $236,567,008
Total Cash per Share MRQ $4.77
Total Debt MRQ $
Total Debt to Equity MRQ 0.00
Current Ratio MRQ 23.77
Book Value per Share MRQ $5.86

Cash Flow

Operating Cash Flow TTM $-81,173,000
Levered Free Cash Flow TTM $-55,270,624

MLYS Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding 49,631,200
Float Shares 22,988,160
Avg 10 Volume 113,227
Avg 30 Volume None
Shares Short 872,859
Short Ratio 7.09
Short % of Shares 2.58%
% Held by Insiders 2.96%
% Held by Institutions 92.47%

Stock Price Summary

Beta
Fifty Two Week Low $5.85
Fifty Two Week High $17.70
Fifty Two Week Change -24.79%
Day 50 MA $13.14
Day 200 MA $10.97

Dividends and Splits

Forward Annual Dividend Rate $
Forward Annual Dividend Yield %
Trailing Annual Dividend Rate $0.00
Trailing Annual Dividend Yield 0.00%
Payout Ratio 0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date